Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.

Br J Cancer · 2023 · PMC10703888 · PMID 37872405

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

SUV TLR of 3 at baseline showed a trend towards shorter PFS, in line with previous reports, which suggests a correlation between poor prognosis and increased FDG uptake in NEN [ 41 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.